SAN FRANCISCO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- On July 29, 2026, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC sued the company over alleged improper business practices. The events have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Hims & Hers might have engaged in un...
Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices. In an interview with CNBC, he also said the company's sale of compounded GLP-1 drugs helped to bring prices for the treatments down.
Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's quarterly results this week said sales for that offering are unlikely to drive revenue growth this year.
Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss options. Revenue for the quarter ended June 30 rose 38% year over year to $753.2 million, topping the roughly $699 mi...
Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast.
Stocks looked set to struggle for direction on Tuesday as investors worried about inflation, with hopes of Iran agreeing a deal to reopen the crucial Strait of Hormuz shipping route fading fast.
Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-loss treatments and international expansion weighed on profitability. The company reported a net loss of 37 cents per share for the quarter, compared with analysts' expectations for a loss of 1 cent...
